Osteopontin levels and increased disease activity in relapsing–remitting multiple sclerosis patients
Authors:
- M.H.J. VogtMVM.H.J. Vogt
- S. FlorisSFS. Floris
- J. KillesteinJKJ. Killestein
- D.L. KnolDKD.L. Knol
- M. SmitsMSM. Smits
- F. BarkhofFBF. Barkhof
- C.H. PolmanCPC.H. Polman
- L. NagelkerkenLNL. Nagelkerken
- 1 October 2004
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 155 (1-2) , 155-160
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Elevated osteopontin levels in active relapsing‐remitting multiple sclerosisAnnals of Neurology, 2003
- Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseasesTrends in Neurosciences, 2002
- Antibody‐mediated suppression of Vβ5.2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trialAnnals of Neurology, 2002
- Osteopontin—a molecule for all seasonsQJM: An International Journal of Medicine, 2002
- The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating DiseaseScience, 2001
- Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) ImmunityScience, 2000
- IL-1 Up-Regulates Osteopontin Expression in Experimental Crescentic Glomerulonephritis in the RatThe American Journal of Pathology, 1999
- Insights into the aetiology and pathogenesis of multiple sclerosisImmunology & Cell Biology, 1998
- Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activityAnnals of Neurology, 1995
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983